Eisai Assigns Its Worldwide Exclusive License for DACOGEN® to Otsuka
WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ — Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico.
In addition, Eisai Inc. has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka.
Eisai’s marketing rights for DACOGEN(®) flow from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai’s global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products across the world through a global network of research facilities, manufacturing sites and marketing subsidiaries. For more information about Eisai’s global operations, please visit www.eisai.com.
Media Inquiries Investor Inquiries Suzanne Grogan Alex Scott Eisai Inc. Eisai Inc. 201-746-2083 201-746-2177 email@example.com firstname.lastname@example.org
SOURCE Eisai Inc.